Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Subjects With Mature B-Cell Malignancies

Next Previous
Trial Profile

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Subjects With Mature B-Cell Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SGR-1505 (Primary)
  • Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions
  • Sponsors Schrodinger

Most Recent Events

  • 14 May 2025 According to a Schrodinger media release, data from this trial will be presented at the European Hematology Association Annual Congress, taking place June 12 - 15, 2025, in Milan, Italy. Additional data from this trial will be presented at the International Conference on Malignant Lymphoma, Company to host webcast to review data on Thursday, June 12, 2025 at 8:00 a.m. ET
  • 07 May 2025 According to a Schrodinger media release, the company expects to report initial clinical data from this trial in June.
  • 13 Jan 2025 According to a Schrodinger media release, initial data from the Phase 1 study to be presented in the first half of 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top